Real‐World Evidence on the Efficacy of Icaritin for Unresectable Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study
International Journal of Cancer · 2026
DOI: 10.1002/ijc.70590 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Dinghu Zhang und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interventional Therapy, Zhejiang Cancer Hospital, Hangzhou, Zhejiang Province, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Flavonoids, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Zhejiang Provincial Natural Science Foundation.
Abstract (Originalsprache)
Icaritin's efficacy was evaluated for unresectable advanced hepatocellular carcinoma (HCC), a major global burden with limited advanced‐stage treatment options. A multicenter retrospective real‐world study (May 2022–May 2024) included 163 patients with unresectable advanced HCC. Treatments were Icaritin monotherapy, Icaritin + anti‐VEGF, or Icaritin + PD‐1 inhibitors + anti‐VEGF. Primary endpoints were progression‐free survival (PFS) and overall survival (OS); secondary endpoints were objective response rate (ORR) and disease control rate (DCR). Subgroup analyses assessed alpha‐fetoprotein (AFP) impact. In first‐line treatment, Icaritin monotherapy achieved an ORR of 26.32%. Combining Icaritin with PD‐1 inhibitors and anti‐VEGF agents increased ORR to 38.30%. Median PFS was 4.27 months for monotherapy; second‐line median OS for Icaritin monotherapy reached 19.91 months. Patients with AFP < 400 ng/mL generally showed numerically better PFS in first‐line regimens compared to those with AFP ≥ 400 ng/mL. Patients with high AFP treated with Icaritin + PD‐1 inhibitors demonstrated a promising response. Icaritin shows promising efficacy in unresectable HCC, particularly in patients with lower AFP levels. The findings support personalized treatment strategies and warrant further research to optimize outcomes and elucidate Icaritin's mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Interventional Therapy, Zhejiang Cancer Hospital, Hangzhou, Zhejiang Province, China.
- Department of Hepatobiliary Surgery, Shulan (Hangzhou) Hospital, Hangzhou, Zhejiang Province, China.
- Interventional Radiology Department, The Affiliated Hospital of Qingdao University (East Campus), Qingdao, Shandong Province, China.
- Department of Interventional Therapy, Shandong Cancer Hospital, Jinan, Shandong Province, China.
- Department of Hepatobiliary Surgery, Sichuan Provincial People's Hospital, Chengdu, Sichuan Province, China.
- Department of Hepatobiliary Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong Province, China.
ORCID-Profile: Hui Zeng
Förderung
- Zhejiang Provincial Natural Science Foundation
Zitieren
APA
Zhang, D., Xie, Q., Zhang, Z., Wang, S., Liu, J., An, X., Liu, K., Yu, Z., Xiang, H., He, Q., Zheng, X., Chang, Z., Du, R., Zhang, L., Li, G., Xu, Q., Song, W., Jin, B., Liu, C., …, & Zeng, H. (2026). Real‐World Evidence on the Efficacy of Icaritin for Unresectable Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study. International Journal of Cancer. https://doi.org/10.1002/ijc.70590
Vancouver
Zhang D, Xie Q, Zhang Z, Wang S, Liu J, An X, et al. Real‐World Evidence on the Efficacy of Icaritin for Unresectable Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study. International Journal of Cancer. 2026. doi:10.1002/ijc.70590
BibTeX
@article{Zhang2026,
author = {Zhang, Dinghu and Xie, Qinfen and Zhang, Zhewei and Wang, Song and Liu, Jibing and An, Xiang and Liu, Kangshou and Yu, Zhengping and Xiang, Huiling and He, Qiang and Zheng, Xin and Chang, Zukuan and Du, Ruijie and Zhang, Li and Li, Gong and Xu, Qingyu and Song, Wenjie and Jin, Bin and Liu, Chongzhong and Li, Jianjun and Zhou, Xu and Li, Wenbin and Yang, Xiaojun and Zhang, Chuanlei and Zeng, Hui},
title = {Real‐World Evidence on the Efficacy of Icaritin for Unresectable Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study},
journal = {International Journal of Cancer},
year = {2026},
doi = {10.1002/ijc.70590}
}
EUVIMED